IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has received a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $48.6875.

Several analysts have recently commented on IDYA shares. Mizuho increased their price objective on IDEAYA Biosciences from $44.00 to $46.00 and gave the company an “outperform” rating in a report on Tuesday, November 11th. Royal Bank Of Canada restated an “outperform” rating and set a $49.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday. Wedbush boosted their price target on IDEAYA Biosciences from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday. Wall Street Zen downgraded shares of IDEAYA Biosciences from a “buy” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Thursday, January 22nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IDYA. Farther Finance Advisors LLC grew its stake in shares of IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after buying an additional 580 shares during the period. ANTIPODES PARTNERS Ltd boosted its position in shares of IDEAYA Biosciences by 49.4% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after buying an additional 380 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in IDEAYA Biosciences in the 3rd quarter valued at about $38,000. Global Retirement Partners LLC acquired a new position in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $61,000. Finally, Abich Financial Wealth Management LLC purchased a new stake in shares of IDEAYA Biosciences during the third quarter worth $58,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Down 2.8%

NASDAQ IDYA opened at $31.98 on Friday. The firm has a market capitalization of $2.81 billion, a price-to-earnings ratio of -24.41 and a beta of 0.10. IDEAYA Biosciences has a 52 week low of $13.45 and a 52 week high of $39.28. The company has a fifty day moving average of $34.19 and a two-hundred day moving average of $30.51.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.09. The company had revenue of $21.75 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same period last year, the firm earned ($1.49) earnings per share. IDEAYA Biosciences’s quarterly revenue was up 55.7% on a year-over-year basis. Equities research analysts anticipate that IDEAYA Biosciences will post -3.07 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.